Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.81 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.81 |
| ▸ | MAP2K1 | Q02750 | 18/20 | 0.59 |
| ▸ | MAP2K2 | P36507 | 3/20 | 0.59 |
| ▸ | RAF1 | P04049 | 1/20 | 0.59 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.59 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.59 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.59 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.59 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.59 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.59 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.59 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29356577 | 0.90 | MEN1 (1.00) | MEN1KMT2ATDP1MAP2K1MAP2K2 | |
| SCHEMBL1801637 | 0.90 | MEN1 (1.00) | MEN1KMT2ATDP1MAP2K1MAP2K2 | |
| SCHEMBL5873131 | 0.89 | MEN1 (0.78) | MEN1KMT2ATDP1MAP2K1MAP2K2 | |
| SCHEMBL5392733 | 0.88 | MEN1 (0.82) | MEN1KMT2ATDP1MAP2K1MAP2K2 | |
| SCHEMBL5391354 | 0.88 | MEN1 (0.82) | MEN1KMT2ATDP1MAP2K1MAP2K2 | |
| SCHEMBL5391642 | 0.86 | MEN1 (0.82) | MEN1KMT2ATDP1MAP2K1MAP2K2 | |
| SCHEMBL5385133 | 0.84 | MEN1 (0.77) | MEN1KMT2ATDP1MAP2K1MAP2K2 | |
| SCHEMBL5379835 | 0.84 | MEN1 (0.77) | MEN1KMT2ATDP1MAP2K1MAP2K2 | |
| SCHEMBL5390931 | 0.84 | MEN1 (0.75) | MEN1KMT2ATDP1MAP2K1MAP2K2 | |
| SCHEMBL6265441 | 0.83 | MEN1 (0.75) | MEN1KMT2ATDP1MAP2K1MAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7001905-B2 | Substituted diarylamines as MEK inhibitors | WARNER-LAMBERT COMPANY (US) | 2006-02-21 | — | — | US | disclosed |
| US-20030225076-A1 | 5-Amide substituted diarylamines as mex inhibitors | BIWERSI CATHLIN (US) | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225076-A1 | 5-Amide substituted diarylamines as mex inhibitors | NRAS, MAPK6, MAPK12 | MEN1 2841/4885KMT2A 636/4885TDP1 851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.